What happened with ELAN today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Elanco Animal Health serves two similarly sized businesses: pet health and farm-animal health, which together generate almost all its revenue. Pet owners need protection against parasites and treatments for conditions such as skin disease and pain. Farmers buy its products to prevent and treat disease and improve livestock productivity. Major sellers include Advantage Family, Seresto and Credelio Family for cats and dogs, Rumensin for cattle, and Maxiban/Monteban for poultry.
Elanco receives payment mainly from distributors, retailers, veterinarians and farm-animal producers rather than directly from pet owners. Veterinarians typically resell its pet products to owners, while retail channels include e-commerce. An affiliate of Cencora, a veterinary distributor, is its largest customer and accounts for a meaningful share of revenue. Demand for flea-and-tick products such as Seresto and Advantage Family makes pet-health sales stronger in the first half of the year.
Sales depend on maintaining product approvals in each market, and new products cannot be marketed without the required approvals or equivalent notices. Rules also constrain how farmers use some products: the EU and Vietnam restrict preventive antibiotics in farm-animal feed.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Elanco depends on pet-treatment demand, livestock producers’ health spending and rival product launches, including those from privately held principal competitor Boehringer Ingelheim Animal Health.
Zoetis competes with Elanco for spending on pet and livestock medicines and vaccines; easier-to-use, more effective or cheaper rival products can pressure Elanco’s sales and prices. Watch Zoetis’s launches in parasite control, skin treatments and pain therapies, where their portfolios overlap.
Phibro Animal Health Corporation competes with Elanco for livestock producers’ spending on antibacterials, anticoccidials, vaccines and products that improve animal performance. Its animal-health sales are the relevant line to watch for competition facing Elanco’s farm-animal business, rather than its industrial ingredients sales.
Merck’s Animal Health business competes with Elanco by selling livestock medicines and vaccines and pet parasite treatments to veterinarians, distributors and animal owners, but human medicines dominate Merck’s overall results. Its Bravecto parasite-treatment sales and animal-health launches are more useful to watch for Elanco than Merck’s total sales.
IDEXX and Elanco both depend on pet owners’ veterinary-care spending: IDEXX sells diagnostic tests and services to veterinary practices, while Elanco sells pet treatments through veterinarians, distributors and retailers. IDEXX’s Companion Animal Group is the business to watch for that shared demand, rather than its water-testing business.
Elanco depends on Cencora’s veterinary distribution affiliate as its largest customer, accounting for approximately 12% of Elanco’s revenue in 2025. The affiliate buys Elanco products and resells animal-health medicines, vaccines and parasite treatments to pet and livestock customers, making its purchases a direct exposure for Elanco.
Fed Interest Rate Decision
The Fed’s interest-rate decision signals the cost of borrowing across the economy, which can affect what Elanco pays when its debt reprices or it refinances.
Expected4.0%Last release4.0%
If it comes in above expectations
If rates are higher than expected, Elanco may face higher interest costs on debt that reprices or on new borrowing, leaving less cash for its animal-health business.
If it comes in below expectations
If rates are lower than expected, Elanco may pay less interest when debt reprices or it borrows anew, leaving more cash available for its animal-health business.
Merck & Co., Inc. earningsMRK
Merck’s animal-health results will show how spending on parasite treatments and rival launches may shape the market for Elanco’s pet medicines.
Focus on Bravecto sales and relevant launches in Merck’s Animal Health business, not Merck’s overall results, which are dominated by human medicines. Steady Bravecto sales or growth from launches would show support for parasite-treatment demand, but could also mean tougher competition for Elanco; weakness could signal softer demand or a rival losing ground, and would not establish that Elanco’s sales fell. The takeaway is how demand and competition in this overlapping treatment market are developing.
Idexx Laboratories Inc earningsIDXX
IDEXX’s companion-animal business will show whether veterinary clinics are using more diagnostic services, a clue to demand in the channel Elanco uses to sell pet treatments.
Watch sales and demand for services in IDEXX’s Companion Animal Group, not its water-testing business. Growth would suggest companion-animal care at clinics is active, a supportive signal for Elanco’s pet treatments sold through veterinarians; weakness could point to pressure in that shared channel, though diagnostic tests and treatments are different purchases. The takeaway is whether the veterinary-care channel both businesses rely on is active.
Cencora, Inc. earningsCOR
Cencora’s report offers clues about veterinary distribution; its affiliate is Elanco’s largest customer and accounted for about 12% of Elanco’s 2025 revenue.
Look for activity in Cencora’s veterinary distribution business and any detail on animal-health purchasing or sales; company-wide results cannot show how much its affiliate bought from Elanco. Steady distribution activity would support the view that this major customer is continuing to move products to pet and farm-animal customers. Weakness could signal pressure on orders or end demand. The takeaway is whether the channel serving a customer that represented about 12% of Elanco’s 2025 revenue is holding up.
ZOETIS INC. earningsZTS
Zoetis’s parasite, skin and pain-treatment sales will show demand and competitive pressure in pet-care categories that overlap with Elanco’s products.
Focus on Zoetis launches and sales in parasite control, skin treatments and pain therapies, rather than its overall results. Growth in those products would show demand in the overlapping categories, but could also mean Zoetis is winning customers from Elanco; weakness could mean less competitive pressure or softer category demand. The takeaway is how demand in Elanco’s overlapping pet-treatment categories is changing and whether Zoetis is pressing harder.
Elanco Animal Health Incorporated earningsThis company
Elanco’s report will show whether sales of new pet treatments and farm-animal products are growing enough to offset manufacturing costs and discounts.
Read Pet Health and Farm Animal sales growth alongside gross margin, the share of sales left after product costs. Growth in both businesses with a steady or wider margin would show that new products and farm-animal demand are adding profitable sales. Rising sales with a falling margin would show that manufacturing costs, discounts or product mix are eating into that growth. The test is whether Elanco’s sales growth is also strengthening product profitability.
